The average time to get a drug to market, crossing FDA hurdles, is 12 years and costs in excess of $1B. And in those twelve years, there is animal testing, human trials, and dozens of other steps that a company needs to go through. TARA Biosystems has found a way to generate human tissue OUTSIDE of the body that can be used in the drug development process to test safety and effectiveness without harming animals or risking human life. CEO Misti Ushio shares some insight on the potential of in vitro biology for drug development, TARA Biosystem’s different lines of business, and recent funding round from investors that include OMX Ventures, Merieux Equity Partners, Partnership Fund for New York City, Trancos Ventures, DEFTA Partners, and Tachyon Ventures.
This company is backed by The Bill and Melinda Gates Foundation, WuXi AppTec’s Corporate Venture Fund, Deerfield Management, Baron, Qiming Venture Partners, and GV (formerly Google Ventures) and is leading innovation in drug discovery.
The entire healthcare industry is working towards to a common goal of bettering humanity but most of the effort is fragmented. The amount of medical research is growing exponentially and there has been no easy way to navigate it. Enter H1. It took around 2 years and millions of dollars for H1 to compile the most […]
Health is a remarkable area for early-stage investment. It shows more activity, more exits, more corporate involvement, and more overall value over the past five years than any other segment. However, it is also an extremely crowded area; the number of active health investors has more than doubled to more than 1500. There has also […]